Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, has reached an agreement with South Korean company PRG S&T to obtain authorization for Progerinin (SLC-D011), an investigational drug for treating Hutchinson-Gilford Progeria Syndrome. Under the agreement, Sentynl will acquire full rights to this FDA-designated orphan drug upon achieving specific milestones, adding a second potential early aging therapy to its rare disease product portfolio. The oral small molecule candidate targets harmful progeria proteins and is currently undergoing Phase IIA clinical trials, with data expected by mid-2026.